Prime Medicine Inc [NASDAQ: PRME] jumped around 0.45 points on Monday, while shares priced at $3.82 at the close of the session, up 13.35%.
Prime Medicine Inc stock is now -3.54% down from its year-to-date (YTD) trading value. PRME Stock saw the intraday high of $3.82 and lowest of $3.33 per share. The company’s 52-week high price is 6.94, which means current price is +244.14% above from all time high which was touched on 10/06/25.
Compared to the average trading volume of 3.69M shares, PRME reached a trading volume of 8336645 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Prime Medicine Inc [PRME]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PRME shares is $6.46 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PRME stock is a recommendation set at 1.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Citigroup have made an estimate for Prime Medicine Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on May 27, 2025. The new note on the price target was released on May 20, 2025, representing the official price target for Prime Medicine Inc stock.
The Price to Book ratio for the last quarter was 4.26, with the Price to Cash per share for the same quarter was set at 1.18.
How has PRME stock performed recently?
Prime Medicine Inc [PRME] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 8.37. With this latest performance, PRME shares dropped by -29.91% in over the last four-week period, additionally plugging by 186.14% over the last 6 months – not to mention a rise of 30.82% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PRME stock in for the last two-week period is set at 42.21, with the RSI for the last a single of trading hit 0.46, and the three-weeks RSI is set at 0.48 for Prime Medicine Inc [PRME]. The present Moving Average for the last 50 days of trading for this stock 4.98, while it was recorded at 3.60 for the last single week of trading, and 3.11 for the last 200 days.
Prime Medicine Inc [PRME]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Prime Medicine Inc [PRME] shares currently have an operating margin of -3412.48% and a Gross Margin at -19.83%. Prime Medicine Inc’s Net Margin is presently recorded at -3301.64%.
Prime Medicine Inc (PRME) Capital Structure & Debt Analysis
According to recent financial data for Prime Medicine Inc. ( PRME), the Return on Equity (ROE) stands at -112.34%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -54.98%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Prime Medicine Inc’s Return on Invested Capital (ROIC) is -72.49%, showcasing its effectiveness in deploying capital for earnings.
Prime Medicine Inc (PRME) Efficiency & Liquidity Metrics
Based on Prime Medicine Inc’s (PRME) latest financial statements, the Debt-to-Equity Ratio is 0.73%, indicating its reliance on debt financing relative to shareholder equity.
Prime Medicine Inc (PRME) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Prime Medicine Inc. (PRME) effectively leverages its workforce, generating an average of -$922149.53 per employee. The company’s liquidity position is robust, with a Current Ratio of 6.61% and a Quick Ratio of 6.61%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Prime Medicine Inc [PRME]
With the latest financial reports released by the company, Prime Medicine Inc posted -0.31/share EPS, while the average EPS was predicted by analysts to be reported at -0.31/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PRME. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Prime Medicine Inc go to 19.22%.
Insider trade positions for Prime Medicine Inc [PRME]
There are presently around $60.35%, or 73.26%% of PRME stock, in the hands of institutional investors. The top three institutional holders of PRME stocks are: ALPHABET INC. with ownership of 15.06 million shares, which is approximately 12.6375%. ARK INVESTMENT MANAGEMENT LLC, holding 6.13 million shares of the stock with an approximate value of $$31.49 million in PRME stocks shares; and ARK INVESTMENT MANAGEMENT LLC, currently with $$31.25 million in PRME stock with ownership which is approximately 5.1002%.
